| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/01/2006 | CA2277990C 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines |
| 08/01/2006 | CA2269217C New 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives |
| 08/01/2006 | CA2234611C New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 08/01/2006 | CA2198701C Substituted 9-alkyladenines |
| 07/27/2006 | WO2006079077A2 Use of diltiazem or analogs thereof as modulators of ghrelin receptor |
| 07/27/2006 | WO2006078753A1 N-substituted heterocyclic sulfonamides |
| 07/27/2006 | WO2006078610A1 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| 07/27/2006 | WO2006078006A1 Indole compound and pharmaceutical composition containing the same |
| 07/27/2006 | WO2006077954A1 Remedy for neurological disease |
| 07/27/2006 | WO2006077853A1 Therapeutic agent for sensory abnormality |
| 07/27/2006 | WO2006077846A1 Therapeutic agent for attention-deficit hyperactivity disorder |
| 07/27/2006 | WO2006077495A1 Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
| 07/27/2006 | WO2006077487A1 3,4-dihydro-2-naphthamide derivatives and their therapeutic applications |
| 07/27/2006 | WO2006077212A1 Use of oxycodone for treating visceral pain |
| 07/27/2006 | WO2006077026A1 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (glyt-i) inhibitors for the treatment of neurological and neuropsychiatry disorders |
| 07/27/2006 | WO2006058720A3 Novel compounds for the treatment of neurological disorders |
| 07/27/2006 | WO2006055260A3 Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
| 07/27/2006 | WO2006029275A3 Methods of using death receptor ligands and cd20 antibodies |
| 07/27/2006 | US20060168672 B7-like molecules and uses thereof |
| 07/27/2006 | US20060167261 e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty |
| 07/27/2006 | US20060167251 CCR9 inhibitors and methods of use thereof |
| 07/27/2006 | US20060167087 Substituted aniline derivatives |
| 07/27/2006 | US20060167084 Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis |
| 07/27/2006 | US20060167078 Substituted benzodioxepins |
| 07/27/2006 | US20060167076 Acutumine and acutumine compounds synthesis and use |
| 07/27/2006 | US20060167064 Pharmaceutical liquid composition containing pyridone derivative |
| 07/27/2006 | US20060167052 Piperidine derivative, process for producing the same, and use |
| 07/27/2006 | US20060167050 Combined use of methylphenidate and melatonin for treating attention-deficit hyperactive disorder |
| 07/27/2006 | US20060167049 Terphenly derivatives, preparation thereof, compositions containing same |
| 07/27/2006 | US20060167048 N-4-piperidinyl compounds as ccr5 modulators |
| 07/27/2006 | US20060167042 antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation |
| 07/27/2006 | US20060167038 2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide; preventive, therapeutic agent and analgesic for overactive bladder |
| 07/27/2006 | US20060167036 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 07/27/2006 | US20060167034 Novel benzonaphthyridines |
| 07/27/2006 | US20060167032 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/27/2006 | US20060167026 Antipsychotic molecular-targeting epithelial growth factor receptor |
| 07/27/2006 | US20060167016 drugs which stimulate guanylate cyclase such as 1-(2-Fluorobenzyl)-3-{5-[(1S,5R)-1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl]-2-pyrimidinyl}-1H-pyrazol[3,4-b]pyridine, used for prophylaxis of nervous system disorders |
| 07/27/2006 | US20060167007 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 07/27/2006 | US20060167005 New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine |
| 07/27/2006 | US20060167004 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 07/27/2006 | US20060167003 Probucol derivatives |
| 07/27/2006 | US20060167002 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 07/27/2006 | US20060167001 Pyridazinone-derivatives as pde4 inhibitors |
| 07/27/2006 | US20060167000 veterinary medicine; neurodegenerative diseases; Alzheimers's Disease |
| 07/27/2006 | US20060166999 Use of microsomal triglyceride transfer protein (MTP) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (PPTRL) |
| 07/27/2006 | US20060166993 Substituted at the 2 position with an aminophenyl group, e.g., 4-[5,7-Dimethyl-4-(3,4,5-trimethoxyphenoxy)imidazo[5,1-f][1,2,4]triazin-2-yl]-aniline; prophylaxis and treatment of cancer, neurodegenerative disorders such as Parkinson's disease, and psychiatric disorders such as schizophrenia. |
| 07/27/2006 | US20060166992 Heterocyclically substituted imidazotriazines |
| 07/27/2006 | US20060166978 Inhibitors of IkB kinase (I Kappa B Kinase); 1-acetyl-7-bromo- beta -carboline; antiinflammatory and anticarcinogenic agent; asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, infections, and cardiac infarct |
| 07/27/2006 | US20060166976 Compositions and methods for treating or preventing convulsions or seizures |
| 07/27/2006 | US20060166967 Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain |
| 07/27/2006 | US20060166965 Atypical antipsychotic agents having low affinity for the D2 receptor |
| 07/27/2006 | US20060166961 Cell adhesion inhibitors |
| 07/27/2006 | US20060166940 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases |
| 07/27/2006 | US20060166927 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 07/27/2006 | US20060166903 Phosphocholine linked prodrug derivatives |
| 07/27/2006 | US20060166868 Vegf peptides and their use |
| 07/27/2006 | US20060166865 A modified nucleoside comprising a purine ring for treating viral infections |
| 07/27/2006 | US20060166325 Glial cell line-derived neurotrophic factor receptor |
| 07/27/2006 | US20060166275 Amyloid beta protein (globular assembly and uses thereof) |
| 07/27/2006 | US20060166202 proteins comprising an amino acid sequence including the catalytic region and regulatory domains; the protein inhibits neurite retraction in an (lysophosphatidic acid) LPA-induced neurite retraction bioassay; used for treating nervous system disorders and/or injuries |
| 07/27/2006 | US20060165822 For use in treatment of Parkinson's Disease and L-Dopa therapy; controlled release; solvent extraction; kits |
| 07/27/2006 | US20060165816 Herbal compositions useful as chemopreventive and therapeutic agents |
| 07/27/2006 | US20060165815 Choline-silicic acid complex with osmolytes and divalent trace elements |
| 07/27/2006 | US20060165792 Controlled release oxycodone compositions |
| 07/27/2006 | US20060165791 Oral dosage form prepared by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules; improving efficiency and quality of pain management |
| 07/27/2006 | US20060165757 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/27/2006 | US20060165696 Remedy for spinal injury containing interleukin-6 antagonist |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165683 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 07/27/2006 | US20060165681 Antibodies to myelin associated glycoprotein (MAG); neurological diseases/disorders |
| 07/27/2006 | US20060165604 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; migraines |
| 07/27/2006 | DE20023785U1 Composition useful for e.g. treating nervous system disorders, comprising botulinum neurotoxin, is free from natural complexing proteins and is not antigenic |
| 07/27/2006 | CA2604394A1 Hyaluronic acid derivative and neural stem cells for sci and pnt regeneration |
| 07/27/2006 | CA2601326A1 2,5-disubstituted phenyl methanone derivatives as glycine transporter 1(glyt-i) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/27/2006 | CA2595208A1 Therapeutic agents for sensory disorders |
| 07/27/2006 | CA2595173A1 N-substituted heterocyclic sulfonamides |
| 07/27/2006 | CA2595043A1 Use of oxycodone for treating visceral pain |
| 07/27/2006 | CA2594940A1 Cgrp receptor antagonists |
| 07/27/2006 | CA2594781A1 Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-related diseases |
| 07/27/2006 | CA2594563A1 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| 07/27/2006 | CA2562685A1 Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| 07/26/2006 | EP1683863A2 A method for enhancing neurone survival and agents useful for same |
| 07/26/2006 | EP1683805A1 Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
| 07/26/2006 | EP1683803A1 Water soluble prodrugs of hindered alcohols or phenols |
| 07/26/2006 | EP1683798A1 Novel fused polycyclic compound having heterocycle and medicinal use thereof |
| 07/26/2006 | EP1683797A1 Heterocyclic spiro compound |
| 07/26/2006 | EP1683790A1 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands |
| 07/26/2006 | EP1683527A1 Method of inhibiting secretase activity |
| 07/26/2006 | EP1683519A1 Preventive/therapeutic agent for speech disorder |
| 07/26/2006 | EP1682550A1 Substituted naphthyridinone derivatives |
| 07/26/2006 | EP1682523A1 Morpholine derivatives as norepinephrine reuptake inhibitors |
| 07/26/2006 | EP1682521A1 Macrocyclic lactams and pharmaceutical use thereof |
| 07/26/2006 | EP1682503A2 Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 07/26/2006 | EP1682502A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 07/26/2006 | EP1682162A1 Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions |
| 07/26/2006 | EP1682157A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
| 07/26/2006 | EP1682155A1 Analgesia method |
| 07/26/2006 | EP1682153A2 Methods of modulating angiogenesis and cancer cell proliferation |
| 07/26/2006 | EP1682152A2 Compositions and methods for treatment of nervous system disorders |
| 07/26/2006 | EP1682141A1 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain |